Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley
This article was originally published in The Tan Sheet
Executive Summary
Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened